托伐普坦起始时尿渗透压即刻下降预测ADPKD肾脏预后
结果显示,起始托伐普坦当晚尿渗透压从基线351.8 ± 142.2 mOsm/kg H2O降至97.6 ± 23.8 mOsm/kg H2O,且1个月后门诊随访仍维持下降,但1个月时尿渗透压变异性更大(160.2 ± 83.8 mOsm/kg H2O)。多因素分析显示,基线eGFR、基线尿蛋白及入院当日傍晚尿渗透压变化(初始尿渗透压下降)与随后年度eGFR变化显著相关。
要点
- 托伐普坦起始当晚尿渗透压从基线351.8 ± 142.2降至97.6 ± 23.8 mOsm/kg H2O。
- 1个月后尿渗透压仍维持下降,但变异性增大(160.2 ± 83.8 mOsm/kg H2O)。
- 基线eGFR、基线尿蛋白和初始尿渗透压下降与年度eGFR变化显著相关。
核心结论
- 尿渗透压可简便快速测量,托伐普坦起始后短时间内尿渗透压变化可能是临床实践中判断肾脏预后的有用指标。
主要发现
- 托伐普坦起始前尿渗透压均值为351.8 ± 142.2 mOsm/kg H2O,当晚降至97.6 ± 23.8 mOsm/kg H2O。
- 1个月后门诊随访尿渗透压仍维持下降,但1个月时尿渗透压值变异性更大(160.2 ± 83.8 mOsm/kg H2O),高于起始当晚。
- 多因素分析显示,基线eGFR、基线尿蛋白及入院当日傍晚尿渗透压变化(初始尿渗透压下降)与随后年度eGFR变化显著相关。
临床怎么用
- 尿渗透压可简便快速测量,托伐普坦起始后短时间内尿渗透压变化可能有助于在实际临床实践中判断肾脏预后。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tolvaptan, a vasopressin V2 receptor antagonist, is used for treating autosomal dominant polycystic kidney disease (ADPKD). We focused on changes in urinary osmolality (U-Osm) after tolvaptan initiation to determine whether they were associated with the therapeutic response to tolvaptan. METHODS: This was a single-centre, prospective, observational cohort study. Seventy-two patients with ADPKD who received tolvaptan were recruited. We analysed the relationship between changes in U-Osm and annual estimated glomerular filtration rate (eGFR) in terms of renal prognostic value using univariable and multivariable linear regression analyses. RESULTS: The mean value of U-Osm immediately before tolvaptan initiation was 351.8 ± 142.2 mOsm/kg H2O, which decreased to 97.6 ± 23.8 mOsm/kg H2O in the evening. The decrease in U-Osm was maintained in the outpatient clinic 1 month later. However, the 1-month values of U-Osm showed higher variability (160.2 ± 83.8 mOsm/kg H2O) than did those in the first evening of tolvaptan administration. Multivariate analysis revealed that the baseline eGFR, baseline urinary protein and U-Osm change in the evening of the day of admission (initial U-Osm drop) were significantly correlated with the subsequent annual change in eGFR. CONCLUSIONS: U-Osm can be measured easily and rapidly, and U-Osm change within a short time after tolvaptan initiation may be a useful index for the renal prognosis in actual clinical practice.
引用
- Akihisa T, Kataoka H, Makabe S, et al. Immediate drop of urine osmolality upon tolvaptan initiation predicts impact on renal prognosis in patients with ADPKD. Nephrol Dial Transplant. 2024. PMID: 37935473. doi:10.1093/ndt/gfad232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。